Oxford BioTherapeutics is a clinical-stage oncology biotechnology company developing first-in-class, antibody-based cancer therapies. Its work centres on targeted treatments such as antibody-drug conjugates, immuno-oncology antibodies, T-cell engagers, CAR-T approaches, bispecifics and radiopharmaceuticals. The company uses its proprietary OGAP®-Verify proteomic discovery platform to identify and validate novel membrane protein targets in patient tumours and the tumour microenvironment. Its integrated capabilities span target discovery, validation, antibody or binder generation, therapeutic optimisation and IND-enabling development.
